Loading patent…
AssigneeRigel Pharmaceuticals, Inc.
InventorsHenry Lu, Weiqun Li, David Anderson
Estimating the term…
The present invention relates to methods of screening for target polypeptides that bind to RNA, using affinity purification methods, and the use of such target polypeptide for drug discovery and in methods of treating and preventing disease, e.g., HCV infection.
A method of screening for polypeptides that bind to an RNA, the method comprising the steps of:
A method of screening for polypeptides that bind to an RNA, the method comprising the steps of:
A method of screening for polypeptides that bind to an RNA comprising an IRES, the method comprising the steps of:
A method of screening for polypeptides that bind to an RNA comprising an IRES, the method comprising the steps of:
A method of screening for polypeptides that bind to an HCV RNA, the method comprising the steps of:
The method of claim 61, wherein the HCV RNA comprises an IRES sequence.
A method of screening for polypeptides that bind to an HCV RNA, the method comprising the steps of:
A method for assaying for compounds that modulate HCV replication and/or translation, the method comprising the steps of:
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
From the US filing history. Foreign family members aren’t listed.
Backward citations are indexed for grants only.
Linear peptides containing only normal peptide links: having 5 to 11 amino acids
Linear peptides containing only normal peptide links: having 12 to 20 amino acids
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: from viruses
From vertebrates: from mammals
Term end not estimated
Not applicable.
Not applicable.
The present invention relates to methods of screening for target polypeptides that bind to RNA, using affinity purification methods, and the use of such target polypeptide for drug discovery and in methods of treating and preventing disease, e.g., HCV infection.
The following example is provided by way of illustration only and not by way of limitation. Those of skill in the art will readily recognize a variety of noncritical parameters that could be changed or modified to yield essentially similar results.
Example 1 describes a method of identifying a polypeptide using an RNA molecule ligated to a biotin labeled DNA oligonucleotide.
HCV IRES RNA (approximately 360 bases) was combined with DNA oligonucleotide (pAACAGCTATGACCAZGAZZGX; wherein p is phosphate, Z is biotinylated thymidine and X is 3′ terminator), RNA ligase and buffer at 37° C. for 1.5 hours. The RNA ligated to biotin labeled oligonucleotide (heretofore referred to as “ligated RNA”) was purified and stored at −80° C. until further use.